Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Biotron ( (AU:BIT) ) has provided an update.
Biotron Limited has successfully raised $1,274,589 through an Entitlement Issue to support its ongoing commercialization and research activities. The company completed the first stage of an animal study for its lead HBV compound, confirming its safety, and is advancing towards assessing its antiviral efficacy. Collaborating with C14 Consulting Group, Biotron is seeking strategic partnerships to enhance its antiviral portfolio. The company also appointed a new Non-Executive Director, Mr. Michael Medway, to strengthen its leadership team.
More about Biotron
Biotron Limited is a biotechnology company focused on the development and commercialization of antiviral programs. The company is primarily engaged in creating therapeutic solutions for viral infections, with a particular emphasis on its lead clinical asset BIT225 and a promising Hepatitis B virus (HBV) program.
Technical Sentiment Signal: Sell
Current Market Cap: A$3.32M
Learn more about BIT stock on TipRanks’ Stock Analysis page.